<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487929</url>
  </required_header>
  <id_info>
    <org_study_id>HULP051937</org_study_id>
    <nct_id>NCT00487929</nct_id>
  </id_info>
  <brief_title>Oxidative Stress and Cardiovascular Morbidity in Sleep Apnea-Hypopnea Syndrome (SAHS)</brief_title>
  <acronym>OSCAMSA</acronym>
  <official_title>Phase 4 Study of the Relationship Between the Oxidative Stress and the Development of Cardiovascular Complications in the Sleep Apnea-hypopnea Syndrome (SAHS). Effect of the Treatment With CPAP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the levels of 8-isoprostane and other oxidative
      stress biomarkers in plasma and condensed exhaled air between patients with SAHS and
      cardiovascular complications, patients with SAHS without cardiovascular complications and
      control subjects. To evaluate the effect of three months of treatment with CPAP on the
      oxidative stress biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To compare the levels of 8-isoprostane and other oxidative stress biomarkers in plasma
      and condensed exhaled air between patients with SAHS and cardiovascular complications,
      patients with SAHS without cardiovascular complications and control subjects. To evaluate the
      effect of three months of treatment with CPAP on the oxidative stress biomarkers.

      Design: randomized, double blind, of parallel groups and controlled with placebo study.

      Study subjects: 53 patients with SAHS (23 with cardiovascular complications and 30 without
      cardiovascular complications), 23 patients with cardiovascular diseases without SAHS and 23
      control subjects.

      Interventions: Three months of treatment with therapeutic CPAP or with sham CPAP (placebo).

      Determinations: clinical (cardiovascular morbidity) and anthropometric data. Fat free
      corporal mass, echocardiography, spirometry, ambulatory monitoring of the arterial pressure,
      endothelial reactivity. Oxidative stress biomarkers (8-isoprostane, homocysteine, HIF-1,
      NFkB, AP-1, VEGF, ET-1, TNF-alpha, IL-1, IL-6, ICAM-1, VCAM-1, nitrates and nitrites) in
      plasma and condensed exhaled air.Peripheral sensitivity to hypoxia. Urinary excretion of
      catecholamines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasmatic 8-isoprostane concentration</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasmatic and condensed exhaled air concentrations of homocysteine, HIF-1, NFkB, AP-1, VEGF, ET-1, TNF-alpha, IL-1, IL-6, ICAM-1, VCAM-1, nitrates and nitrites.</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous positive airway pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham CPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham nasal continuous positive airway pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nasal CPAP</intervention_name>
    <description>Nocturnal</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham CPAP</intervention_name>
    <description>Nocturnal</description>
    <arm_group_label>Sham CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sleep apnea-hypopnea syndrome (AHI &gt; 5)

          -  Excessive sleepiness (ESS &gt; 11)

          -  No previous CPAP treatment

        Exclusion Criteria:

          -  Blood pressure &gt; 180/120 mmHg.

          -  Secondary hypertension

          -  Professional driver

          -  COPD, asthma, bronchiectasis, lung cancer, restrictive lung disorder, chest wall
             disease

          -  Neuromuscular disease or thyroid function abnormalities

          -  Morbid obesity (BMI &gt; 40 Kg/m2).

          -  Respiratory infection in the 2 last months.

          -  Anemia (Hb &lt; 10 g/dl) or polyglobulia (Hct &gt; 55%).

          -  Diurnal hypercapnia (PaCO2 &gt; 45 mmHg) or moderate hypoxemia (PaO2 &lt; 70 mmHg).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco García-Rio, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Servicio de Neumología. Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2007</study_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2013</last_update_posted>
  <responsible_party>
    <name_title>Francisco Garcia-Rio</name_title>
    <organization>Hospital Universitario La Paz</organization>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>morbidity</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>cpap</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

